What is Perlara?
Perlara operates at the vanguard of the biotechnology sector, offering a specialized service known as Guided Cures. By deploying a team of expert researchers and clinicians, the firm facilitates modality-agnostic virtual consulting and model-agnostic drug repurposing. This innovative framework allows Perlara to navigate the intricate landscape of rare diseases and personalized medicine, effectively democratizing access to high-level scientific inquiry. The company's market position is bolstered by its ability to synthesize global research efforts into personalized treatment strategies, making it an essential partner for families and scientists seeking to accelerate the discovery of new therapeutic interventions.
How much funding has Perlara raised?
Perlara has raised a total of $9.4M across 2 funding rounds:
Angel/Seed
$2M
Unspecified
$7.4M
Angel/Seed (2014): $2M, investors not publicly disclosed
Unspecified (2017): $7.4M led by Novartis, Y Combinator, Radical Investments, Haystack Fund, Pivotal Capital Alpha, Al-Hamra Group, and Homebrew Ventures
Key Investors in Perlara
Novartis
Novartis is a global pharmaceutical manufacturer headquartered in Switzerland, specializing in developing and producing innovative medications and healthcare solutions. The company focuses on research and development of treatments across multiple therapeutic areas to address various medical conditions and improve patient outcomes worldwide.
Y Combinator
Established in 2005 and located in Mountain View, California, Y Combinator provides seed funding for startup businesses and acts as a prominent accelerator for high-growth technology ventures.
Homebrew Ventures
Homebrew is a San Francisco-based venture capital firm that focuses on early-stage investments, providing both capital and strategic guidance to emerging companies in the technology and biotech sectors.
What's next for Perlara?
With the support of its latest strategic backing, Perlara is well-positioned to expand its operational footprint and deepen its research capabilities. The company is expected to focus on enhancing its drug repurposing pipelines and scaling its virtual consulting infrastructure to accommodate a broader range of medical conditions. As the biotech industry increasingly shifts toward precision medicine, Perlara's model-agnostic approach provides a scalable solution to the persistent challenges of drug development. Future growth will likely involve deeper integration with global research networks and the continued refinement of its clinical decision-support tools, ensuring that the firm remains at the forefront of medical innovation.
See full Perlara company page
